Pharmacologic therapy for nonalcoholic fatty liver disease in adults

Pharmacotherapy

Volumn 33, Issue 2, 2013, Pages 223-242

  Malinowski, Scott S ^a   Byrd, Jennifer S ^b   Bell, Allison M ^a   Wofford, Marion R ^c   Riche, Daniel M ^a,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNION UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Fatty liver; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pioglitazone; Statin

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; FENOFIBRATE; GLITAZONE DERIVATIVE; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; POLYUNSATURATED FATTY ACID; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; BODY ODOR; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED HEADACHE; EPISTAXIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LEG EDEMA; LIVER BIOPSY; MYALGIA; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREVALENCE; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANIMALS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METFORMIN; PHARMACEUTICAL PREPARATIONS; THIAZOLIDINEDIONES;

EID: 84875468890     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1190     Document Type: Review

References (74)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-50.
2. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
4. Tran TT, Changsri C, Shackleton CR, et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol 2006;21:381-3.
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
6. Bambha K, Belt P, Abraham M, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012;55:769-80.
7. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-23.
8. Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301: G825-34.
9. Tacer KF, Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011. doi:10.1155/2011/783976.
10. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
11. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011;17:2801-11.
12. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther 2008;25:1141-74.
13. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22.
14. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
15. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721-7.
16. Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
17. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176- 84.
18. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
19. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008;135:100-10.
20. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-8.
21. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-15.
22. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34:1255-64.
23. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
24. Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60.
25. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009;2:157-63.
26. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
27. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46:1082-90.
28. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:223-34.
29. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-8.
30. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-4.
31. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-8.
32. Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201.
33. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-9.
34. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011;10:277-86.
35. Buranawati W, Thoun-U-Thaisri P, Pramoolsinsup C, Wisedopas N, Atamasirikul K, Udomsubpayakul U. Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): a randomized, placebo controlled study. Thai J Gastroenterol 2007;8:57-63.
36. Santos VN, Lanzoni VP, Szejnfeld D, Shiqueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with non-alcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003;36:723- 9.
37. Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in sub-jects with non-alcholic fatty liver disease: a double-blind, placebo- controlled trial. Ann Hepatol 2004;3:108-12.
38. Ersoz F, Gunsar F, Karasu Z, Akay A, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005;16:124-8.
39. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011-9.
40. Leuschner UFH, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatits: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-9.
41. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for the treatment of non-alcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
42. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40:194-9.
43. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395-400.
44. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006;23:1143-51.
45. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007;52:2512-9.
46. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
47. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80- 6.
48. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23.
49. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebocontrolled trial of ursodeoxycholic acid with vitamin E in non-alcoholic steatohepatits. Clin Gastroenterol Hepatol 2006;4:1537-43.
50. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of mulitifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin 2006;22:873-83.
51. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7.
52. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131-4.
53. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011;54:1631-9.
54. Georgescu EF, Georgescu M. Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007;16: 39-46.
55. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
56. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011;55:1383- 90.
57. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9.
58. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-53.
59. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterologival Assocation. Hepatology 2012;55:2005-23.
60. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Rogue M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;20(3):CD002966.
61. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7.
62. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646- 50.
63. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22.
64. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with nonalcoholic fatty liver disease. Lipids Health Dis 2011;10:49.
65. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
66. Neuman M, Angulo P, Malkiewicz I, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002;17:196-202.
67. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal b-oxidation, PPARa, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001;281:G1333-9.
68. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARa agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004;39:1286-96.
69. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987;237:885-8.
70. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fisher 344 rats. Hepatology 2004;39:608-16.
71. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
72. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
73. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
74. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009;29:1184-8.